Remove 2016 Remove Communication Remove Vaccines
article thumbnail

CureVac gets an early date in Covid-19 vaccine patent case with Pfizer/BioNTech

Pharmaceutical Technology

The Covid-19 pandemic saw a proliferation in novel vaccine technologies being produced rapidly. With the emergence of vaccines came accusations of technology encroachment amongst biotech companies. CureVac’s lawsuits add to a complex legal landscape for Pfizer/BioNTech that already includes ones from Moderna.

Vaccines 116
article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Campaigners challenge NHS England’s latest plan to share patient data

pharmaphorum

People can opt out of the scheme by filling in a form and taking it to their GP before 23 June, but campaigners say this has not been communicated effectively. The government’s last attempt to shake up patient data-sharing – 2013’s Care.data scheme – suffered from a number of false starts and was eventually shut down in 2016.

article thumbnail

Treatment for all: the key steps to better representation in pharma

pharmaphorum

As the vaccines were developed and rolled out, the disparity in their take up among different sections of the community highlighted how excluded some minority communities felt from areas of healthcare. And then the COVID-19 pandemic really brought it into sharp relief.

Vaccines 122
article thumbnail

Innovation across the healthcare system is needed to realise the value of medicines

pharmaphorum

Medicines and vaccines are among the most powerful interventions that can help improve quality of life for people across the world. Data will always be central to everything we do, as it has the power to communicate the potential of a new treatment to change a person’s life.

article thumbnail

Streamlining Postapproval Submissions Using ICH Q12 & SCDM

ISPE

BioProcess International 14 (2016): 38–43. Ideally, data and information from multiple regions could be submitted simultaneously, available for all regulatory bodies to access and review as required, thereby allowing regulators to communicate with each other and see previous questions and decisions of other regulatory bodies.

article thumbnail

Accommodating Multiple Modalities in the Same Facility

ISPE

ATMP facilities are different from conventional pharmaceutical facilities that process other traditional modalities, such as vaccines and monoclonal antibodies (mAbs), and often require heightened segregation and smaller footprints. Viral antigen vaccines. For example: Live vaccine manufacturing. Complete Data Gathering.